leadf
logo-loader
viewParadigm Biopharmaceuticals Ltd
(
ASX:PAR
)

Paradigm Biopharmaceuticals completes $35 million capital raising

The company aims to develop and commercialise its safe and effective treatment for sufferers of osteoarthritis.

Paradigm Biopharmaceuticals Ltd - Paradigm Biopharmaceuticals completes $35 million capital raising
The funds will be used for the Phase 3 clinical trial

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has placed A$35 million in shares to leading Australian and international institutional and sophisticated investors with bids received exceeding the size of the placement.

The placement was priced at $1.30 per share, which represents a 23.1% discount to Paradigm’s last trading price of $1.69 per share.

Proceeds will be applied to costs of the second Phase 3 osteoarthritis (OA) clinical trial and leaves Paradigm fully-funded through to completion of this trial for which readout is expected to take place in late 2022.

"Endorsement" of PAR

Paradigm chief executive officer Paul Rennie said the receipt of firm commitments for the placement indicated the growing confidence in Zilosul in the treatment of OA along with Paradigm’s pathway to regulatory approval and commercialisation.

He said: “The strong support shown by leading institutional investors both domestic and international, is a huge endorsement of the company and its aim of developing and commercialising safe and effective treatment for sufferers of osteoarthritis.”

Completion of the placement is expected to occur on or around Wednesday, April 15, 2020.

Rennie said: “The proceeds from the placement will ensure the company is fully-funded through the completion of the Phase 3 trial and ensure we can be singularly focused on executing the trial and delivering outcomes for patients in this very large and growing market.”

Path to regulatory approval

The capital raising enables Paradigm to focus on the clear path to regulatory approval and commercialisation.

PAR recently received clear guidance from the US Food and Drug Administration (FDA) around the primary and secondary endpoints for its Phase 3 OA trial.

This guidance includes the number of phase three studies required for registration and overall clarity and guidance for the requirements of Phase 3 clinical trial design and new drug application submission.

Quick facts: Paradigm Biopharmaceuticals Ltd

Follow
ASX:PAR

Price: 2.22 AUD

Market Cap: $515.72 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Paradigm Biopharmaceuticals secures first revenues for Zilosul

Paradigm Biopharmaceuticals Ltd's (ASX:PAR) (OTCMKTS:PBIGF) Dr Jeannie Joughin tells Proactive's Andrew Scott they've received first revenue through physician prescription of Zilosul® to patients via the Therapeutic Goods Administration (TGA) pay-for-use Special Access Scheme (SAS). Under the...

on 20/5/21

2 min read